Key Investment Considerations Relating to Much Anticipated CAR-T Product Launches By Kite and Novartis Later This YearInvestment Conclusions: Cryoport: My recommended best way to invest in CAR-T launches (CYRX, Buy, $3.60) Kite Pharma: Analysis of Six Month Data from ZUMA-1 That Led to 40% Price Increase (KITE, Underperform, $72.53)Report Preface In the event that you are unfamiliar with acronyms used widely in this report such as CAR-T, DLBCL, TFL,… Kite Pharma: Highlights of October 18, 2016 Analysts' Day- I Remain More Cautious on the Stock than Mainstream Wall Street Analysts (KITE, Avoid, $46.45)Key Points; The most important data point between now and yearend 2016 is release of data from ZUMA-1 that shows… Kite Pharma: Interpretation of Results from the Interim Look at ZUMA-1 (KITE, Avoid, $60.25)Overview Kite released a press release with topline data on the interim look at the ZUMA-1 trial. This note interprets information… Kite Pharma Part 5: Detailed Research That I Have Done In Coming to My Opinion on Kite (KITE, Avoid, $$54.06)Investment Opinion Kite will be reporting interim results of the phase 2, ZUMA-1 trial of its lead product KTE-C19 by the… Kite Pharma Part 4: A Preview of Highly Anticipated Results from Interim Look at ZUMA-1 (KITE, Avoid, $54.95)Key Points: I think that an imminent press release dealing with topline results from an interim look at the ZUMA-1… Kite Pharma Part 3: A Detailed Analysis of the Design of the All-Important ZUMA-1 TrialReport Overview This is the third part of the series of reports that I have written on Kite Pharmaceuticals. I… Kite Pharma Part 2: An Overview of CAR-T Cell Drug Development EffortsOverview This section tries to give a brief, layman’s overview on the potential role of CAR-T cells in treating certain hematological… Kite Pharma: Part 1- Glossary of Terms and AcronymsIntroduction I have been working on a report on Kite for over three months and have in front of me a… Comments on Antares, Kite Pharma and Northwest BiotherapeuticsSmithOnStocks Mailbox My mailbox comments are brief articles on stocks in which I am involved. These can come from… CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?Introduction to This Thought Piece Emerging biotechnology stocks obviously are very hard to value on an absolute basis because they usually… |
